Theragenics Announces Stockholder Approval of Merger Agreement with Juniper
17 Octobre 2013 - 3:27PM
Business Wire
Theragenics Corporation® (NYSE: TGX) (the “Company”), a medical
device company serving the surgical products and prostate cancer
treatment markets, announced today that the stockholders of the
Company voted to approve the previously announced merger agreement
providing for a newly formed affiliate of Juniper Investment
Company, LLC to acquire all of the outstanding common stock of the
Company for $2.20 per share in cash.
Over 96% of the votes cast at today’s special meeting were voted
in favor of the Merger Agreement, representing approximately 64% of
the Company’s outstanding common stock as of September 16, 2013,
the record date for the special meeting.
Upon the closing of the transaction, the Company’s common stock
will no longer be publicly traded, and the Company will be a wholly
owned subsidiary of an affiliate of Juniper Investment Company,
LLC. The Company expects that the transaction will be completed as
promptly as practicable, subject to customary closing
conditions.
Shortly after the transaction is completed, stockholders of
record will receive a letter of transmittal and instructions on how
to surrender their shares of the Company’s common stock to the
paying agent in exchange for payment of the merger consideration.
Stockholders of record should wait to receive the letter of
transmittal before surrendering their shares.
Forward Looking Statements
Certain matters discussed in this report may be forward-looking
statements. These forward-looking statements are based on current
expectations, estimates, forecasts and projections of future
company or industry performance based on management’s judgment,
beliefs, current trends and market conditions. Actual outcomes and
results may differ materially from what is expressed, forecasted or
implied in any forward-looking statement. Forward-looking
statements may be identified by the use of words such as “will,”
“expects,” “intends,” “plans,” “anticipates,” “believes,” “seeks,”
“estimates,” and similar expressions. There are a number of risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements included in this
document. These include, but are not limited to: (i) consents or
approvals required for the transaction may not be obtained, or may
delay the transaction or result in the imposition of conditions
that could have a material adverse effect on the Company or cause
the parties to abandon the transaction; (ii) conditions to the
closing of the transaction may not be satisfied; (iii) the outcome
of any legal proceedings to the extent initiated against the
Company and others following the announcement of the transaction
cannot be predicted; (iv) the business of the Company may suffer as
a result of uncertainty surrounding the transaction; and (v) the
Company may be adversely affected by other economic, business,
and/or competitive factors. Other factors that could cause the
Company’s actual results to differ materially from those expressed
or implied are discussed under “Risk Factors” in the Company’s most
recent annual report on Form 10-K and other filings with the SEC.
The Company undertakes no obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. Readers are cautioned not to place undue reliance on
these forward-looking statements.
Theragenics CorporationFrank Tarallo, CFO &TreasurerorLisa
Rassel, Manager of Investor Relations800-998-8479 -
770-271-0233www.theragenics.com
Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theragenics (NYSE:TGX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024